» Articles » PMID: 18398622

Impact of Rapamycin on Liver Regeneration

Overview
Journal Virchows Arch
Date 2008 Apr 10
PMID 18398622
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The remarkable capacity of the liver to regenerate after injury and the prospects of organ self-renewal have attracted much interest in the understanding and modulation of the underlying molecular events. We investigated the effect of mammalian target of rapamycin (mTOR) inhibitor rapamycin (RAPA) on liver by correlating intravital microscopy, immunohistochemistry, and reverse transcriptase polymerase chain reaction in a rat model of 2/3 hepatectomy. RAPA significantly retarded proliferation of hepatocytes, endothelial cells, and hepatic stellate cells (HSCs) mostly between days 2 and 4 after hepatectomy and downregulated major cytokines and growth factors (tumor necrosis factor alpha, hepatocyte growth factor, platelet-derived growth factor, platelet-derived growth factor receptor, insulin-like growth factor-1, transforming growth factor beta 1) important for liver regeneration. These effects were almost absent at later time points. RAPA also had a transient, but broad effect on angiogenesis, and impaired sinusoidal density as well as mRNA levels of vascular endothelial growth factor, vascular endothelial growth factor receptor 1, vascular endothelial growth factor receptor 2, and angiopoietin-1. Activation of HSC was also transiently suppressed as observed by smooth muscle protein 1 alpha protein expression and intercellular adhesion molecule-1 mRNA levels. The rate of apoptosis in liver was significantly increased by RAPA between day 3 and day 7. The effect of RAPA on liver repair, angiogenesis, and HSC activation is confined to the phase of active cell proliferation. This transient effect might allow further exploration of mTOR inhibitors in clinical situations that involve liver regeneration, and seems to have implications beyond immunosuppression.

Citing Articles

Arterial Infusion of Rapamycin in the Treatment of Rabbit Hepatocellular Carcinoma to Improve the Effect of TACE.

Wu T, Yao Y, Sun R, Wang H, Yin X, Zhang J Open Life Sci. 2021; 13:299-304.

PMID: 33817096 PMC: 7874725. DOI: 10.1515/biol-2018-0036.


Modulation of Autophagy: A Novel "Rejuvenation" Strategy for the Aging Liver.

Xu F, Tautenhahn H, Dirsch O, Dahmen U Oxid Med Cell Longev. 2021; 2021:6611126.

PMID: 33628363 PMC: 7889356. DOI: 10.1155/2021/6611126.


Liver Regeneration after Hepatectomy and Partial Liver Transplantation.

Yagi S, Hirata M, Miyachi Y, Uemoto S Int J Mol Sci. 2020; 21(21).

PMID: 33182515 PMC: 7665117. DOI: 10.3390/ijms21218414.


The Role of Autophagy for the Regeneration of the Aging Liver.

Xu F, Hua C, Tautenhahn H, Dirsch O, Dahmen U Int J Mol Sci. 2020; 21(10).

PMID: 32443776 PMC: 7279469. DOI: 10.3390/ijms21103606.


mTORC2 Signaling Is Necessary for Timely Liver Regeneration after Partial Hepatectomy.

Xu M, Wang H, Wang J, Burhan D, Shang R, Wang P Am J Pathol. 2020; 190(4):817-829.

PMID: 32035060 PMC: 7180798. DOI: 10.1016/j.ajpath.2019.12.010.


References
1.
Palmes D, Spiegel H . Animal models of liver regeneration. Biomaterials. 2003; 25(9):1601-11. DOI: 10.1016/s0142-9612(03)00508-8. View

2.
Nelsen C, Rickheim D, Tucker M, Hansen L, Albrecht J . Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem. 2002; 278(6):3656-63. DOI: 10.1074/jbc.M209374200. View

3.
Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J . PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature. 2006; 442(7104):779-85. DOI: 10.1038/nature05029. View

4.
Park J, Ha H, Ahn H, Kang S, Kim Y, Seo J . Sirolimus inhibits platelet-derived growth factor-induced collagen synthesis in rat vascular smooth muscle cells. Transplant Proc. 2005; 37(8):3459-62. DOI: 10.1016/j.transproceed.2005.09.066. View

5.
Guba M, Yezhelyev M, Eichhorn M, Schmid G, Ischenko I, Papyan A . Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 2005; 105(11):4463-9. DOI: 10.1182/blood-2004-09-3540. View